| Title： | Expert consensus on BRAF inhibitors for the treatment of malignant solid tumors |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Diagnosis and Treatment |
| Countries and regions： | China |
| Guidelines users： | Clinician and other professionals in the diagnosis and treatment of malignant solid tumors |
| Evidence classification method： | "a. Evidence level: 1A, global indications, clear recommendations from domestic and foreign guidelines, accessibility to domestic medication, rigorous meta-analysis, large-scale randomized controlled studies, with ≥ 80% expert recognition; 1B, with clear recommendations from domestic and foreign guidelines, accessible domestic medication, rigorous meta-analysis, large-scale randomized controlled trials, and 60% to 80% expert recognition; 2A, Meta analysis of domestic medication accessibility, general quality, small randomized controlled studies, well-designed large-scale retrospective studies, case-control studies, with ≥ 80% expert recognition; 2B, general quality meta-analysis, small randomized controlled studies, well-designed large-scale retrospective studies, case-control studies, 60% to 80% expert recognition; 3. Non controlled single arm clinical studies, case reports, expert opinions, with an expert recognition rate of less than 60%. b. Recommendation level: Strongly recommended, all (100%) experts reach a consensus on recommendation; Recommendation: More than 75% (≥ 75%, but<100%) of experts reach a consensus on recommendations; It can be considered that more than 50% (≥ 50%, but<75%) of experts reach a consensus on recommendations; Not recommended, consensus reached among experts below 50% (<50%)." |
| Development unit： | 1.Oncology Society of Chinese Medical Association；2.Chinese Society of Clinical Oncology Expert Committee On Rare Tumors |
| Registration time: | 2024-02-19 |
| Registration number： | PREPARE-2024CN254 |
| Purpose of the guideline: | Promote and guide the standardized application of BRAF inhibitors in the field of malignant solid tumors |
Latest registration
